论文部分内容阅读
目的探讨皮下脂膜炎样T细胞淋巴瘤(subcu taneous pann icu litis like T-ce ll lym phom a,SPTCL)的临床病理特征、治疗及预后。方法对15例SPTCL患者的HE染色切片及免疫组化、临床、治疗方法,结合目前的相关文献对其组织形态学、免疫组化、临床特征、疗效及影响预后因素进行总结和分析。结果治疗有效率(CR+PR)83.4%,其中CR 41.7%。伴有HPS患者易复发,为预后不良因素。TCR基因克隆性重排、白细胞减少及乳酸脱氢酶升高也可能为预后的不良指标。结论SPTCL是一种罕见的的非霍奇金淋巴瘤(non-Hodgk in’s lym phom a,NHL),主要累及皮下脂肪组织。CHOP方案对部分患者治疗有效,但易复发,预后差。
Objective To investigate the clinicopathological characteristics, treatment and prognosis of subcu panniculitis-like T-cell lymphoma (SPTCL). Methods 15 cases of SPTCL were stained with HE, immunohistochemically, clinically and therapeutically. The histopathology, immunohistochemistry, clinical features, curative effect and prognostic factors were summarized and analyzed according to the current literature. Results The treatment response rate (CR + PR) was 83.4%, of which CR was 41.7%. Easy to relapse with HPS patients, poor prognosis factor. TCR gene clonal rearrangements, leukopenia and elevated lactate dehydrogenase may also be an adverse prognostic indicator. Conclusion SPTCL is a rare non-Hodgkin’s lymphoma (NHL) that mainly affects subcutaneous adipose tissue. CHOP program for some patients effective treatment, but easy to relapse, the prognosis is poor.